Interested in an injectable PrEP study?
The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting HIV—also known as pre-exposure prophylaxis (PrEP).
The Purpose 2 study is evaluating an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, to see if it helps to reduce the chance of getting HIV through sex.
Everyone who enrolls in the study will receive a daily pill and an injection given under the skin every 6 months. Of the injection and the pill, one will be the active drug and one will be a placebo. Neither you nor the study doctor will know which medication is active and which is placebo. The active drug may be lenacapavir (2 out of 3 chance) or emtricitabine/tenofovir disoproxil fumarate (also known as F/TDF or Truvada) (1 out of 3 chance).
Participants will also be asked to give blood for lab tests and HIV/STI testing.
You may be eligible to participate if:
- You are 18 years or older,
- are HIV negative,
- identify as a cisgender man, trans woman, trans man, or a non-binary person,
- and are currently having receptive anal sex.
For their time and travel, eligible participants can receive up to $175 per visit.
Send us a note using the form below and we’ll ring you back to see if you’re eligible for the study. It’s that simple!
